Peptide Therapeutics Market Size Projected to Reach $80.59 billion by 2034 | 5.9%

According to Straits Research, the global peptide therapeutics market valued at $48.11 billion in 2025, is projected to grow from $50.95 billion in 2026 to $80.59 billion by 2034 at a CAGR of 5.9% during the forecast period 2026–2034.

Researchers have used peptides to deliver drugs to target cells due to their remarkable efficacy and selectivity towards the different receptors on target cells. Several peptide therapies have already been given market authorization and are approved to treat various illnesses. Research and development of innovative medications and technological improvements in peptide therapies are the primary drivers of the global peptide therapeutics market.

Market Dynamics

Rising Cases of Cancer and Metabolic Diseases and Technological Advancements Drives the Global Market

The adoption of peptide therapies will increase due to the rise in cancer cases and metabolic diseases like osteoporosis, obesity, and diabetes. Due to the increasing number of affected pediatric children and the prevalence of target diseases in low-income countries, there is a strong demand for effective and cost-effective medications. The overall cost of manufacturing therapeutic peptides has decreased due to technological advancements, which has encouraged suppliers and manufacturers to seek out newer processes and work with longer and more complex chains of peptides. In addition, the reduction in total costs associated with the production of therapeutic peptides has increased the production of therapeutic peptides.

Rising Incidents of Chronic Diseases Creates Tremendous Opportunities

According to the World Health Organization, chronic diseases such as cancer, diabetes, and cardiovascular disease are the leading causes of morbidity and mortality worldwide (WHO). The prevalence of chronic diseases has increased globally, affecting people from all socioeconomic backgrounds. The market is anticipated to be driven by the rising incidence of chronic diseases, which increases the demand for efficient medications.

Regional Analysis

North America is the most significant shareholder in the global peptide therapeutics market due to the rise in awareness of peptide therapy products, the increase in demand for diagnostics in cancer and other disorders, and the expansion of the biotechnology industry. In addition, increased government spending on R&D is anticipated to support peptide therapies in maintaining their dominance during the forecast period.

Key Highlights

• The global peptide therapeutics market valued at $48.11 billion in 2025, is projected to grow from $50.95 billion in 2026 to $80.59 billion by 2034 at a CAGR of 5.9% during the forecast period 2026–2034.
• Based on application, the market is divided into cancer, metabolic, cardiovascular disorder, respiratory, GIT, anti-infection, pain, dermatology, CNS, and renal.The metabolic segment dominates the global peptide therapeutics market due to growing sedentarism, terrible eating habits, and excessive alcohol consumption.
• Based on product, the market is divided into generic and innovative.The generic segment is anticipated to increase quickly during the forecast period.
• Based on the type of manufacturer, the market is divided into in-house and outsourced.The category of in-house manufacturing held the most significant revenue share due to rigorous regulations, high costs associated with outsourcing, and significant players' growing involvement in developing peptide therapies in-house.
• Based on the route of administration, the market is divided into the parenteral route, oral route, pulmonary, and mucosal.The parenteral administration dominates the market due to the high acceptance rate, faster medicine delivery, and simple application.
• Based on synthesis technology, the market is divided into Solid Phase Peptide Synthesis (SPPS), Liquid Phase Peptide Synthesis (LPPS), and Hybrid Technology.The LPPS segment is the most dominant due to the increasing need for pure peptides to develop effective medicines.
• North America is the most significant global peptide therapeutics market shareholder.

Market Segments

1. By Application
   1. Cancer
   2. Metabolic
   3. Cardiovascular Disorder
   4. Respiratory
   5. GIT
   6. Anti-infection
   7. Pain
   8. Dermatology
   9. CNS
   10. Renal
2. By Type
   1. Generic
   2. Innovative
3. By Type of Manufacturers
   1. In-house
   2. Outsourced
4. By Route of Administration
   1. Parenteral Route
   2. Oral Route
   3. Pulmonary
   4. Mucosal
5. By Synthesis Technology
   1. Solid Phase Peptide Synthesis (SPPS)
   2. Liquid Phase Peptide Synthesis (LPPS)
   3. Hybrid Technology